PURPOSE: It is still unclear if pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients treated for rectal cancer causes worse postoperative outcomes, especially after transanal total mesorectal excision (TaTME). Worse postoperative outcomes might be an argument for an organ preserving watch and wait strategy in fragile patients and patients with comorbidities. The aim of this study is to evaluate whether patients treated for rectal cancer who had pCR to neoadjuvant therapy develop worse postoperative outcomes after TaTME than patients without complete response. METHODS: Comparative retrospective analysis (with nearest neighbor matching algorithm) of postoperative outcomes in two groups of patients, with pCR, n = 15 and without pCR (non-pCR), n = 57. All patients were operated on only by one surgical approach, TaTME, for middle and distal rectal tumors. All procedures were performed by one surgical team between 2014 and 2020 at the University Hospital Brno in Czech Republic. RESULTS: Overall morbidity was comparable between the groups (pCR group - 53.8% vs. non-pCR - 38.6%, p = 0.381). Anastomotic leak (AL) was observed in 33.3% of patients with pCR and in 17.5% of patients in the non-pCR group without statistical significance (p = 0.281). CONCLUSION: In conclusion, pathological complete response after neoadjuvant therapy does not appear to affect postoperative morbidity in rectal cancer after TaTME. Therefore, in patients with complete response who are not adherent to W&W surveillance, surgical resection can be perform without increased postoperative complications.

Department of Surgery Faculty of Medicine University Hospital Brno Bohunice Masaryk University Brno Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

See more in PubMed

Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo L-J, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44. https://doi.org/10.1016/S1470-2045(10)70172-82 . PubMed DOI

Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28. https://doi.org/10.1002/bjs.8702 . PubMed DOI

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17:1471–1474. https://doi.org/10.1245/s10434-010-0985-4 .

Pox C, Aretz S, Bischoff S, et al. S3-Leitlinie Kolorektales Karzinom Version 1.0 - Juni 2013 AWMF-Registernummer: 021/007OL. Z Für Gastroenterol. 2013;51:753–854. https://doi.org/10.1055/s-0033-1350264 . DOI

National Comprehensive Cancer Network. Rectal Cancer (version 1.2021). 2021. https://www.nccn.org/professionals/physician_gls/default.aspx#rectal . Accessed 7 September 2021.

Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae .

Rahbari NN, Weitz J, Hohenberger W, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery. 2010;147:339–51. https://doi.org/10.1016/j.surg.2009.10.012 . PubMed DOI

Campa-Thompson M, Weir R, Calcetera N, Quirke P, Carmack S. Pathologic processing of the total mesorectal excision. Clin Colon Rectal Surg. 2015;28:043–52. https://doi.org/10.1055/s-0035-1545069 . DOI

Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19–23. https://doi.org/10.1007/s003840050072 . PubMed DOI

van der Sluis FJ, Couwenberg AM, de Bock GH, Intven MPW, Reerink O, van Leeuwen BL, van Westreenen HL. Population-based study of morbidity risk associated with pathological complete response after chemoradiotherapy for rectal cancer. Br J Surg. 2020;107:131–9. https://doi.org/10.1002/bjs.11324 . PubMed DOI

Landi F, Espín E, Rodrigues V, Vallribera F, Martinez A, Charpy C, Brunetti F, Azoulay D, de’Angelis N,. Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy. Int J Colorectal Dis. 2017;32:255–64. https://doi.org/10.1007/s00384-016-2685-4 . PubMed DOI

Duldulao MP, Lee W, Le M, Wiatrek R, Nelson RA, Chen Z, Li W, Kim J, Garcia-Aguilar J. Surgical complications and pathologic complete response after neoadjuvant chemoradiation in locally advanced rectal cancer. Am Surg. 2011;77:1281–5. PubMed DOI

Maggiori L, Bretagnol F, Aslam MI, Guedj N, Zappa M, Ferron M, Panis Y. Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision? Surgery. 2014;155:468–75. https://doi.org/10.1016/j.surg.2013.10.020 . PubMed DOI

Horisberger K, Hofheinz RD, Palma P, Volkert AK, Rothenhoefer S, Wenz F, Hochhaus A, Post S, Willeke F. Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity? Int J Colorectal Dis. 2008;23:257–64. https://doi.org/10.1007/s00384-007-0408-6 . PubMed DOI

Wolf JH, Hung YC, Cox S, Aghedo B, Mavanur A, Svoboda S, D’Adamo CR. Pathologic complete response is associated with decreased morbidity following rectal cancer resection. Am J Surg. 2021;222(2):390–4. https://doi.org/10.1016/j.amjsurg.2020.11.050 (Epub 2020 Nov 28 PMID: 33261851). PubMed DOI

Yang J, Wang W, Luo Y, Huang S, Fu Z. Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis. Tech Coloproctol. 2022;26:163–74. https://doi.org/10.1007/s10151-021-02564-y . PubMed DOI

Zaborowski AM, Stakelum A, Winter DC. Anastomotic leak risk in complete responders to neoadjuvant therapy for rectal cancer: a systematic review. Int J Colorectal Dis. 2021;36:671–6. https://doi.org/10.1007/s00384-021-03833-w . PubMed DOI

Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, Park SC, Oh JH, Yu A, Nam B-H. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Res Treat. 2016;48:998–1009. https://doi.org/10.4143/crt.2015.254 . PubMed DOI

Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, Moran B, Hanna GB, Mortensen NJ, Tekkis PP, International TaTME Registry Collaborative. Incidence and risk factors for anastomotic failure in 1594 patients treated by transanal total mesorectal excision: results from the International TaTME Registry. Ann Surg. 2019;269:700–11. https://doi.org/10.1097/SLA.0000000000002653 . DOI

Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, Campos FG, Kiss DR, Gama-Rodrigues J,. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Trans Meet Am Surg Assoc. 2004;122:309–16. https://doi.org/10.1097/01.sla.0000141194.27992.32 . DOI

Serum concentrations of proinflammatory biomarker interleukin-6 (IL-6) as a predictor of postoperative complications after elective colorectal surgery